Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

481
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
481
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

1.9K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.9K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

463
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
463
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

353
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
353
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

520
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
520
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

402
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
402

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to the Letter to the Editor regarding, "Comparison of wear behavior of occlusal device materials manufactured by different processes".

The Journal of prosthetic dentistry·2026
Same author

Determining the perceptibility and acceptability threshold of the relative translucency parameter- A pilot study.

Journal of prosthodontics : official journal of the American College of Prosthodontists·2026
Same author

Factors Affecting Patient Treatment Duration in an Advanced Orthodontic Education Clinic.

Journal of dental education·2025
Same author

Comparison of wear behavior of occlusal device materials manufactured by different processes.

The Journal of prosthetic dentistry·2025
Same author

Effect of surface priming on the wettability of heat-polymerized polymethylmethacrylate, milled and 3D printed denture base polymers: An in vitro study.

Journal of dentistry·2025
Same author

Effect of surface treatment on the bond strength of chairside hard liners bonded to traditional and contemporary CAD-CAM denture base polymers.

The Journal of prosthetic dentistry·2025

Related Experiment Video

Updated: Jul 25, 2025

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

785

The Physical Compatibility of Glycopyrrolate and Rocuronium.

Austen L Weeks1, John Sotos2, Bryce Woolsey3

  • 1Dentist Anesthesiologist, Graduate of The Ohio State University College of Dentistry Dental Anesthesiology Program, Class of 2021, Columbus, Ohio.

Anesthesia Progress
|June 28, 2023
PubMed
Summary

This study confirms the physical compatibility of glycopyrrolate and rocuronium. The combination showed no signs of instability, such as color change or precipitate formation, in various containers over 60 minutes.

Keywords:
Drug compatibilityDrug interactionsGlycopyrrolateIntravenous administrationRocuronium

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.8K
Minimally Invasive Murine Laryngoscopy for Close-Up Imaging of Laryngeal Motion During Breathing and Swallowing
07:22

Minimally Invasive Murine Laryngoscopy for Close-Up Imaging of Laryngeal Motion During Breathing and Swallowing

Published on: December 1, 2023

577

Related Experiment Videos

Last Updated: Jul 25, 2025

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

785
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.8K
Minimally Invasive Murine Laryngoscopy for Close-Up Imaging of Laryngeal Motion During Breathing and Swallowing
07:22

Minimally Invasive Murine Laryngoscopy for Close-Up Imaging of Laryngeal Motion During Breathing and Swallowing

Published on: December 1, 2023

577

Area of Science:

  • Pharmacology
  • Pharmaceutical Science

Background:

  • Limited scientific literature exists on the physical compatibility and stability of combined glycopyrrolate and rocuronium.
  • Ensuring drug compatibility is crucial for safe and effective medication administration.

Purpose of the Study:

  • To analytically confirm the physical compatibility of glycopyrrolate and rocuronium mixtures.
  • To assess the stability of glycopyrrolate and rocuronium when combined in various pharmaceutical preparations.

Main Methods:

  • Glycopyrrolate and rocuronium were combined in different containers.
  • The mixtures were observed for 60 minutes, with assessments including color change, precipitate formation, Tyndall beam test, turbidity, and pH.
  • Statistical analyses were performed to evaluate the significance of observed trends.

Main Results:

  • No significant color change or precipitate formation was observed.
  • The Tyndall beam test and turbidity measurements were not significantly positive.
  • No significant alterations in pH were detected, irrespective of the container used.

Conclusions:

  • Based on the study's protocol, glycopyrrolate and rocuronium were found to be physically compatible.
  • The findings support the potential for co-administration or co-formulation of these two drugs.